



## Veracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024

February 8, 2024

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Feb. 8, 2024-- [Veracyte, Inc.](#) (Nasdaq: VCYT) announced today that it will release financial results for the fourth quarter and full-year 2023 after the close of market on Thursday, February 22, 2024. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.

The conference call will be webcast live from the company's website and will be available via the following link: <https://edge.media-server.com/mmc/p/tkiac6t9>. A webcast replay will be available following the conclusion of the live broadcast and will be accessible on the company's website at <https://investor.veracyte.com/events-presentations>.

The conference call dial-ins can be accessed by registering at: <https://register.vevent.com/register/BI38de228ea0a04e0ab786cfe56be5ca1b>

### About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our Veracyte Diagnostics Platform delivers high-performing cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and a powerful evidence-generation engine, which ultimately drives durable reimbursement and guideline inclusion for our tests, along with new insights to support continued innovation and pipeline development. For more information, please visit [www.veracyte.com](http://www.veracyte.com) or follow us on [LinkedIn](#) or [X \(Twitter\)](#).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20240208633506/en/): <https://www.businesswire.com/news/home/20240208633506/en/>

### Investors

Shayla Gorman  
[investors@veracyte.com](mailto:investors@veracyte.com)  
(619) 393-1545

### Media

Tracy Morris  
[media@veracyte.com](mailto:media@veracyte.com)  
(650) 380-4413

Source: Veracyte, Inc.